|
| |
BioPortfolio's Approved Drugs DatabaseTarcevaErlotinib HydrochlorideDownload PDF containing detailed information.
Press Releases About Tarceva:
|
 |
| Former Pfizer Global R&D President John LaMattina Joins PureTech Ventures as Senior Partner; PureTech Announces Partner Promotions |
10th November, 2009 |
PureTech Ventures |
BOSTON, Nov. 10 /PRNewswire/ -- PureTech Ventures today announced that John LaMattina, Ph.D., former President, Pfizer Global Research & Development and Executive Vice President, Pfizer, Inc., has
|
| Reportlinker Adds Cancer Therapeutics 2006: Market Dynamics and R&D Trends |
5th November, 2009 |
Reportlinker |
-- 133 tables/graphs/diagrams illustrating historical sales data, growth
rates and market share by product, class, therapeutic category, and
company, company portfolios, pipelines
|
| Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report |
24th September, 2009 |
Reportlinker |
-- SERMS
The report includes market share by type of cancer and market share by company for each of the three major segments. It also includes statistical information for cancers by type
|
| Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non-Small-Cell Lung Cancer Drug Market to Nearly Triple to Almost $10 Billion in 2018 |
29th June, 2009 |
Decision Resources |
Emerging Agents from Pfizer, AstraZeneca, GlaxoSmithKline, Bayer/Onyx and Boehringer Ingelheim, and Increased Use of Existing Agents from Eli Lilly and Roche Will Drive Growth, According to a New
|
| Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer |
28th May, 2009 |
Bayer HealthCare Pharmaceuticals Inc. |
WAYNE, N.J., EMERYVILLE, Calif. and MELVILLE, N.Y., May 28 /PRNewswire-FirstCall/ -- Bayer HealthCare LLC., Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and
|
Companies working in the area of Tarceva from Bioportfolio's Biocorporate database : | |
| Company Name | |
OSI Pharmaceuticals is committed to “shaping medicine and changing lives” by developing and commercializing high-quality and novel pharmaceutical products that extend life or improve the quality of...
www.osip.com/ View full profile
| |
This page has been viewed 37 times
Recent Search Terms used to find this page: .
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Tarceva across BioPortfolio, or for Tarceva Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|
